CDC advisory committee wants vaccine effectiveness data for H1N1 component but that is not the predominant strain this season; AstraZeneca is not giving up.
AstraZeneca PLC's FluMist (live attenuated influenza vaccine, LAIV) faces hurdles in winning back the endorsement of a Centers for Disease Control and Prevention advisory panel. But although it may take years to get the necessary vaccine effectiveness data, the company says it is committed to the product.
At its Feb. 22 meeting, CDC's Advisory Committee on Immunization Practices (ACIP) discussed whether data expected in the next couple...
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
